EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study

Si Fang iD, James Yarmolinsky iD, Dipender Gill iD, Caroline J Bull iD, Claire M Perks iD, PRACTICAL Consortium, George Davey Smith iD, Tom R Gaunt iD, Tom G Richardson iD

PLOS Medicine · 03.01.2023 · 20 (1) · e1003988

DOI: 10.1371/journal.pmed.1003988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 03.01.2023. Verfasst von Si Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Prostatic Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically proxied inhibition of LDL-c-lowering drug targets on risk of PrCa. Methods and findings Single-nucleotide polymorphisms (SNPs) associated with LDL-c ( P < 5 × 10 −8 ) from the Global Lipids Genetics Consortium genome-wide association study (GWAS) ( N = 1,320,016) and located in and around the HMGCR , NPC1L1 , and PCSK9 genes were used to proxy the therapeutic inhibition of these targets. Summary-level data regarding the risk of total, advanced, and early-onset PrCa were obtained from the PRACTICAL consortium. Validation analyses were performed using genetic instruments from an LDL-c GWAS conducted on male UK Biobank participants of European ancestry ( N = 201,678), as well as instruments selected based on liver-derived gene expression and circulation plasma levels of targets. We also investigated whether putative mediators may play a role in findings for traits previously implicated in PrCa risk (i.e., lipoprotein a (Lp(a)), body mass index (BMI), and testosterone). Applying two-sample MR using the inverse-variance weighted approach provided strong evidence supporting an effect of genetically proxied inhibition of PCSK9 (equivalent to a standard deviation (SD) reduction in LDL-c) on lower risk of total PrCa (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.76 to 0.96, P = 9.15 × 10 −3 ) and early-onset PrCa (OR = 0.70, 95% CI = 0.52 to 0.95, P = 0.023). Genetically proxied HMGCR inhibition provided a similar central effect estimate on PrCa risk, although with a wider 95% CI (OR = 0.83, 95% CI = 0.62 to 1.13, P = 0.244), whereas genetically proxied NPC1L1 inhibition had an effect on higher PrCa risk with a 95% CI that likewise included the null (OR = 1.34, 95% CI = 0.87 to 2.04, P = 0.180). Analyses using male-stratified instruments provided consistent results. Secondary MR analyses supported a genetically proxied effect of liver-specific PCSK9 expression (OR = 0.90 per SD reduction in PCSK9 expression, 95% CI = 0.86 to 0.95, P = 5.50 × 10 −5 ) and circulating plasma levels of PCSK9 (OR = 0.93 per SD reduction in PCSK9 protein levels, 95% CI = 0.87 to 0.997, P = 0.04) on PrCa risk. Colocalization analyses identified strong evidence (posterior probability (PPA) = 81.3%) of a shared genetic variant (rs553741) between liver-derived PCSK9 expression and PrCa risk, whereas weak evidence was found for HMGCR (PPA = 0.33%) and NPC1L1 expression (PPA = 0.38%). Moreover, genetically proxied PCSK9 inhibition was strongly associated with Lp(a) levels (Beta = −0.08, 95% CI = −0.12 to −0.05, P = 1.00 × 10 −5 ), but not BMI or testosterone, indicating a possible role for Lp(a) in the biological mechanism underlying the association between PCSK9 and PrCa. Notably, we emphasise that our estimates are based on a lifelong exposure that makes direct comparisons with trial results challenging.

Conclusions

Our study supports a strong association between genetically proxied inhibition of PCSK9 and a lower risk of total and early-onset PrCa, potentially through an alternative mechanism other than the on-target effect on LDL-c. Further evidence from clinical studies is needed to confirm this finding as well as the putative mediatory role of Lp(a).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Prostatic NeoplasmsHumansMaleGenome-Wide Association StudyCholesterol, LDLPolymorphism, Single NucleotideTestosteroneMendelian Randomization Analysis

Substanzen

PCSK9 protein, humanProprotein Convertase 9Cholesterol, LDLTestosterone

Autor:innen und Institutionen

  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, United Kingdom.
  • Chief Scientific Advisor Office, Research and Early Development, Novo Nordisk, Copenhagen, Denmark.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
  • Bristol Renal, Bristol Heart Institute, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • IGF & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Learning & Research Building, Southmead Hospital, Bristol, United Kingdom.

ORCID-Profile: Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire M Perks, George Davey Smith, Tom R Gaunt, Tom G Richardson

Förderung

  • Department of Health
  • Medical Research Council
  • Wellcome Trust
  • Cancer Research UK
  • World Cancer Research Fund
  • University Hospitals Bristol NHS Foundation Trust
  • University of Bristol

Zitieren

APA

Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023). Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLOS Medicine, 20(1), e1003988. https://doi.org/10.1371/journal.pmed.1003988

Vancouver

Fang S, Yarmolinsky J, Gill D, Bull CJ, Perks CM, PRACTICAL Consortium, et al. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLOS Medicine. 2023;20(1):e1003988. doi:10.1371/journal.pmed.1003988

BibTeX
@article{Fang2023,
  author = {Fang, Si and Yarmolinsky, James and Gill, Dipender and Bull, Caroline J and Perks, Claire M and PRACTICAL Consortium, PRACTICAL Consortium and Davey Smith, George and Gaunt, Tom R and Richardson, Tom G},
  title = {Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study},
  journal = {PLOS Medicine},
  year = {2023},
  volume = {20},
  number = {1},
  pages = {e1003988},
  doi = {10.1371/journal.pmed.1003988}
}
Kostenlos starten →